Immuno Oncology 2021 and Beyond

After three decades of research, immune-based therapies have become potent new cancer treatments. Recent advances are focused on furthering our understanding of the mechanisms of action and improving access.
MODERATOR:
Mike Teitell, Professor and Director, UCLA Jonsson Comprehensive Cancer Center
SPEAKERS:
Mohamed Abou-el-Enein, Exec. Director, Joint USC/CHLA Cell Therapy Program, USC
Yvonne Chen, Co-Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, UCLA
Ute Dugan, Chief Medical Officer, The Parker Institute for Cancer Immunotherapy
Robert Rickert, SVP, Chief Scienific Officer, Cancer Immunology Discovery, Pfizer
Steven Rosen, Chief Scientific Officer, City of Hope

[@mpoharper]

It is so interesting that the type of tumor affects the focus of their work. One thing not discussed are low mutation burden tumors like those that show up in mucosal melanoma. I would hope you would also look for things that work more broadly.

[@sammychishti-dropshipperaf2177]

Yvonne mentioned CAR T cell therapy. Is this the way to go? to handle disorders. Her skin has brown patches all over.

[@sammychishti-dropshipperaf2177]

How much research has been done on immuno disorders? can these disorders be cured specially after twice bone marrow transplant?? Please advise as my niece is going through this right now and Doctors are in aww as this is very unusual to them that this has came back the third time.